Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines (RVMD) General Counsel Jeff Cislini reported insider trading activity on June 16, 2025. The transaction involved the sale of 1,878 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.5915 to $39.8291.
The sale was conducted under a Rule 10b5-1 trading plan established on May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Cislini's holdings include:
- Total beneficial ownership of 56,005 shares
- 49,054 RSUs included in total holdings
- 160 shares acquired through Employee Stock Purchase Plan on May 31, 2025
This transaction demonstrates a planned, automated sale for tax purposes rather than a discretionary trading decision by the insider.
Revolution Medicines (RVMD) Chief Financial Officer Jack Anders reported a significant insider transaction on June 16, 2025. The CFO disposed of 2,170 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.59 to $39.83.
The sale was conducted under a pre-established Rule 10b5-1 trading plan from May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Anders maintains beneficial ownership of 113,314 shares, which includes:
- 478 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
- 54,213 restricted stock units (RSUs)
This transaction appears to be a routine tax-related sale rather than a discretionary divestment, suggesting no significant change in the executive's long-term position in the company.
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines (NASDAQ: RVMD), reported significant insider trading activity on June 16, 2025. The transaction involved the disposition of 4,289 shares at a weighted average price of $39.83 per share.
The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Kelsey maintains beneficial ownership of 289,414 shares, which includes:
- 94,426 Restricted Stock Units (RSUs)
- 652 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
The transaction prices ranged from $39.60 to $39.83, with the reporting person agreeing to provide detailed price-specific transaction information upon request to relevant parties.
Revolution Medicines (RVMD) Chief Medical Officer Wei Lin reported insider trading activity on June 16, 2025. The transaction involved the sale of 2,173 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.60 to $39.83.
The sale was conducted under a Rule 10b5-1 trading plan established on December 23, 2024, specifically to address tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Lin maintains beneficial ownership of 90,499 shares, which includes:
- 1,021 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
- 64,800 restricted stock units (RSUs)
This transaction represents a planned sale for tax purposes rather than a discretionary trading decision by the insider, as evidenced by the pre-established 10b5-1 plan.